Sodium Hydroxide → 7-methoxy-1-(2-(4-((5,6,7,8-tetrahydroquinoxalin-2-ylmethyl)amino)piperidin-1-yl)ethyl)-1,5-naphthyridin-2(1H)-one hydrochloride

HRID 385636ノート

反応式

HRID 385636 の反応式
[ClH:1].[NH2:2][CH:3]1[CH2:8][CH2:7][N:6]([CH2:9][CH2:10][N:11]2[C:20]3[C:15](=[N:16][CH:17]=[C:18]([O:21][CH3:22])[CH:19]=3)[CH:14]=[CH:13][C:12]2=[O:23])[CH2:5][CH2:4]1.[N:24]1[C:33]2[CH2:32][CH2:31][CH2:30][CH2:29][C:28]=2[N:27]=[CH:26][C:25]=1[CH:34]=O.C(O[BH-](OC(=O)C)OC(=O)C)(=O)C.[Na+].C(=O)([O-])O.[Na+].[OH-].[Na+]>CN(C)C=O.C(OCC)(=O)C.O.C(N(CC)CC)C.C(O)(=O)C>[ClH:1].[CH3:22][O:21][C:18]1[CH:19]=[C:20]2[C:15]([CH:14]=[CH:13][C:12](=[O:23])[N:11]2[CH2:10][CH2:9][N:6]2[CH2:5][CH2:4][CH:3]([NH:2][CH2:34][C:25]3[CH:26]=[N:27][C:28]4[CH2:29][CH2:30][CH2:31][CH2:32][C:33]=4[N:24]=3)[CH2:8][CH2:7]2)=[N:16][CH:17]=1

参加物

11

反応物 5

HCID 14798Sodium HydroxideHCID 516892Sodium BicarbonateHCID 5049666Sodium triacetoxyborohydrideHCID 578154485,6,7,8-Tetrahydroquinoxaline-2-carbaldehydeHCID 689270711-(2-(4-aminopiperidin-1-yl)ethyl)-7-methoxy-1,5-naphthyridin-2(1H)-one hydrochloride

生成物 1

HCID 689255387-methoxy-1-(2-(4-((5,6,7,8-tetrahydroquinoxalin-2-ylmethyl)amino)piperidin-1-yl)ethyl)-1,5-naphthyridin-2(1H)-one hydrochloride収率 49.4%

試薬・触媒・溶媒 5

HCID 176Acetic Acid溶媒HCID 962Water溶媒HCID 6228Dimethylformamide溶媒HCID 8471Triethylamine溶媒HCID 8857Ethyl Acetate溶媒

実験手順

To a solution of 0.13 g of 1-(2-(4-aminopiperidin-1-yl)ethyl)-7-methoxy-1,5-naphthyridin-2(1H)-one hydrochloride in 2.6 mL of N,N-dimethylformamide, 75 mg of 5,6,7,8-tetrahydroquinoxaline-2-carbaldehyde, 0.26 mL of acetic acid, 0.21 mL of triethylamine and 98 mg of sodium triacetoxyborohydride were added, and the mixture was stirred at room temperature for 9 hours 40 minutes. Thereto were added water, a saturated aqueous sodium hydrogen carbonate solution, and ethyl acetate, and the reaction mixture was adjusted to pH 11.5 with a 20% aqueous sodium hydroxide solution, the organic layer was then separated, and the aqueous layer was extracted with ethyl acetate. The organic layer and the extract were combined, the resultant solution was washed with a saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The resultant residue was purified by basic silica gel column chromatography using an eluent of chloroform:methanol=10:1, and thereto were added ethyl acetate and a 4 mol/L hydrogen chloride/ethyl acetate solution. The solvent was distilled off under reduced pressure, diethyl ether was added thereto, and the solid was filtered off to obtain 92 mg of 7-methoxy-1-(2-(4-((5,6,7,8-tetrahydroquinoxalin-2-ylmethyl)amino)piperidin-1-yl)ethyl)-1,5-naphthyridin-2(1H)-one hydrochloride as a light brown solid.

後処理

  1. customthe organic layer was then separated
  2. extractionthe aqueous layer was extracted with ethyl acetate
  3. washthe resultant solution was washed with a saturated aqueous sodium chloride solution
  4. dry with materialdried over anhydrous magnesium sulfate
  5. distillationthe solvent was distilled off under reduced pressure
  6. customThe resultant residue was purified by basic silica gel column chromatography
  7. additionmethanol=10:1, and thereto were added ethyl acetate
  8. distillationThe solvent was distilled off under reduced pressure, diethyl ether
  9. additionwas added
  10. filtrationthe solid was filtered off

出典と根拠

ORDレコード
ord-d6e3db467a0046168fabe89294e5de68
出典データセット
uspto-grants-2013_02
特許番号
US08367831B2

反応ノート

読み込み中…